-
Something wrong with this record ?
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial
R. Pytlík, D. Belada, K. Kubáčková, I. Vášová, T. Kozák, J. Pirnos, I. Bolomská, M. Matuška, J. Přibylová, V. Campr, L. Burešová, A. Sýkorová, A. Berková, P. Klener, M. Trněný, . ,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT12193
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Medline Complete (EBSCOhost)
from 1998-01-01
- MeSH
- Lymphoma, B-Cell drug therapy mortality pathology MeSH
- Cisplatin adverse effects therapeutic use MeSH
- Cyclophosphamide adverse effects therapeutic use MeSH
- Cytarabine adverse effects therapeutic use MeSH
- Adult MeSH
- Doxorubicin adverse effects therapeutic use MeSH
- Etoposide adverse effects therapeutic use MeSH
- Induction Chemotherapy MeSH
- Carmustine adverse effects therapeutic use MeSH
- Consolidation Chemotherapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Melphalan adverse effects therapeutic use MeSH
- Neoplasm Metastasis MeSH
- Methylprednisolone adverse effects therapeutic use MeSH
- Young Adult MeSH
- Antibodies, Monoclonal, Murine-Derived adverse effects therapeutic use MeSH
- Podophyllotoxin adverse effects therapeutic use MeSH
- Prednisone adverse effects therapeutic use MeSH
- Prognosis MeSH
- Disease Progression MeSH
- Antineoplastic Combined Chemotherapy Protocols adverse effects therapeutic use MeSH
- Neoplasm Staging MeSH
- Vincristine adverse effects therapeutic use MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
We have studied the feasibility and efficacy of intensified R-MegaCHOP-ESHAP-BEAM therapy in high-risk aggressive B-cell lymphomas. Altogether 105 patients (19-64 years) with diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBL) or follicular lymphoma grade 3 (FL3) with an age-adjusted International Prognostic Index of 2-3 were recruited. Treatment consisted of three cycles of high-dose R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), followed by three cycles of R-ESHAP (rituximab, etoposide, methylprednisolone, cytarabine, cisplatin) and high-dose consolidation with BEAM (BCNU, etoposide, cytarabine, melphalan) and autologous stem cell transplant. The 5-year progression-free survival (PFS) was 72% (DLBCL 60%, PMBL 89%) and overall survival (OS) was 74% (DLBCL 61%, PMBL 89%) after a median follow-up of 85 months. However, an independent prognostic factor was age only, with patients ≤ 45 years having 5-year PFS 90% and patients > 45 years having PFS 54%. PMBL had better prognosis than DLBCL/FL3 in patients > 45 years (PFS, 88% vs. 48%), but not in younger patients (PFS, 91% vs. 94%).
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16000788
- 003
- CZ-PrNML
- 005
- 20250305093059.0
- 007
- ta
- 008
- 160108s2015 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3109/10428194.2014.904509 $2 doi
- 035 __
- $a (PubMed)24628294
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Pytlík, Robert, $u First Department of Medicine, General University Hospital and First Medical Faculty, Charles University , Prague , Czech Republic. $d 1967- $7 xx0061345
- 245 10
- $a Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial / $c R. Pytlík, D. Belada, K. Kubáčková, I. Vášová, T. Kozák, J. Pirnos, I. Bolomská, M. Matuška, J. Přibylová, V. Campr, L. Burešová, A. Sýkorová, A. Berková, P. Klener, M. Trněný, . ,
- 520 9_
- $a We have studied the feasibility and efficacy of intensified R-MegaCHOP-ESHAP-BEAM therapy in high-risk aggressive B-cell lymphomas. Altogether 105 patients (19-64 years) with diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBL) or follicular lymphoma grade 3 (FL3) with an age-adjusted International Prognostic Index of 2-3 were recruited. Treatment consisted of three cycles of high-dose R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), followed by three cycles of R-ESHAP (rituximab, etoposide, methylprednisolone, cytarabine, cisplatin) and high-dose consolidation with BEAM (BCNU, etoposide, cytarabine, melphalan) and autologous stem cell transplant. The 5-year progression-free survival (PFS) was 72% (DLBCL 60%, PMBL 89%) and overall survival (OS) was 74% (DLBCL 61%, PMBL 89%) after a median follow-up of 85 months. However, an independent prognostic factor was age only, with patients ≤ 45 years having 5-year PFS 90% and patients > 45 years having PFS 54%. PMBL had better prognosis than DLBCL/FL3 in patients > 45 years (PFS, 88% vs. 48%), but not in younger patients (PFS, 91% vs. 94%).
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a myší monoklonální protilátky $x škodlivé účinky $x terapeutické užití $7 D058846
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
- 650 _2
- $a karmustin $x škodlivé účinky $x terapeutické užití $7 D002330
- 650 _2
- $a cisplatina $x škodlivé účinky $x terapeutické užití $7 D002945
- 650 _2
- $a konsolidační chemoterapie $7 D060830
- 650 _2
- $a cyklofosfamid $x škodlivé účinky $x terapeutické užití $7 D003520
- 650 _2
- $a cytarabin $x škodlivé účinky $x terapeutické užití $7 D003561
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a doxorubicin $x škodlivé účinky $x terapeutické užití $7 D004317
- 650 _2
- $a etoposid $x škodlivé účinky $x terapeutické užití $7 D005047
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a indukční chemoterapie $7 D060828
- 650 _2
- $a B-buněčný lymfom $x farmakoterapie $x mortalita $x patologie $7 D016393
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a melfalan $x škodlivé účinky $x terapeutické užití $7 D008558
- 650 _2
- $a methylprednisolon $x škodlivé účinky $x terapeutické užití $7 D008775
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a metastázy nádorů $7 D009362
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a podofylotoxin $x škodlivé účinky $x terapeutické užití $7 D011034
- 650 _2
- $a prednison $x škodlivé účinky $x terapeutické užití $7 D011241
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a vinkristin $x škodlivé účinky $x terapeutické užití $7 D014750
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Belada, David, $d 1972- $7 mzk2006322730
- 700 1_
- $a Kubáčková, Kateřina $7 xx0083614
- 700 1_
- $a Vášová, Ingrid, $d 1965- $7 nlk20000083660
- 700 1_
- $a Kozák, Tomáš, $d 1963- $7 xx0021767
- 700 1_
- $a Pirnos, Jan $7 xx0081863
- 700 1_
- $a Bolomská, Inge $7 xx0329555
- 700 1_
- $a Matuška, Milan, $d 1955- $7 xx0054291
- 700 1_
- $a Přibylová, Jana $7 _AN052982
- 700 1_
- $a Campr, Vít, $d 1960- $7 jo2002148777
- 700 1_
- $a Burešová, Lucie $7 xx0120445
- 700 1_
- $a Sýkorová, Alice, $d 1975- $7 xx0051467
- 700 1_
- $a Berková, Adéla $7 xx0325890
- 700 1_
- $a Klener, Pavel
- 700 1_
- $a Trněný, Marek, $d 1960- $7 nlk20000083659
- 773 0_
- $w MED00003140 $t Leukemia & lymphoma $x 1029-2403 $g Roč. 56, č. 1 (2015), s. 57-64
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24628294 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160108 $b ABA008
- 991 __
- $a 20250305093110 $b ABA008
- 999 __
- $a ok $b bmc $g 1103069 $s 924994
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 56 $c 1 $d 57-64 $e 20140429 $i 1029-2403 $m Leukemia & lymphoma $n Leuk Lymphoma $x MED00003140
- GRA __
- $a NT12193 $p MZ0
- LZP __
- $a Pubmed-20160108
